| Not Yet Recruiting | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) NCT06345027 | Baylor College of Medicine | Phase 1 |
| Unknown | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia NCT06209671 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Recruiting | Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) NCT05010564 | Baylor College of Medicine | Phase 1 |
| Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/S NCT05254743 | Loxo Oncology, Inc. | Phase 3 |
| Recruiting | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773 | MacroGenics | Phase 1 |
| Unknown | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lympho NCT04648475 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse NCT04439721 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Unknown | CAR-T Cells in the Treatment of Malignant Hematological Tumors NCT05619861 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271800 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma NCT04649983 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271410 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia NCT03599375 | jiuwei cui | Phase 1 |
| Withdrawn | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Ly NCT03605589 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Unknown | CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation NCT03564977 | Qingdao Central Hospital | N/A |
| Unknown | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects NCT03598179 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. NCT03614858 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. NCT03229200 | Pharmacyclics Switzerland GmbH | Phase 4 |
| Unknown | Precision Exercise in Children With Malignant Hemopathies NCT04090268 | University of Milano Bicocca | N/A |
| Terminated | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT02518750 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL NCT02848911 | Affimed GmbH | Phase 1 |
| Unknown | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL NCT03564470 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Unknown | A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leu NCT02672501 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies NCT02473757 | National Cancer Institute (NCI) | — |
| Unknown | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies NCT02813837 | Innovative Cellular Therapeutics Co., Ltd. | N/A |
| Completed | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to NCT01087294 | National Cancer Institute (NCI) | Phase 1 |